Silexion
SLXN
Silexion (SLXN) news
Recent news
Silexion Therapeutics Corp - Serum lipid depletion significantly reduces Sil204 gene-knockdown efficiency
AInvest Wire · Sep 28, 2026Silexion Therapeutics Corp - Sil204 achieves robust gene silencing in KRAS cancer cells with physiological serum lipids
AInvest Wire · Sep 28, 2026Silexion Therapeutics reports positive preclinical findings for Sil204, demonstrating key mechanism for endogenous systemic uptake in KRAS-driven cancers
AInvest Wire · Sep 28, 2026Silexion Therapeutics announces pricing of $2.5 million public offering
AInvest Wire · Aug 12, 2026Silexion Therapeutics Corp: Maxim Group adjusts target price to $6 from $60 to reflect 1-for-10 reverse stock split
Silexion Therapeutics Corp (SLXN) has announced a 1-for-10 reverse stock split, effective May 29, 2026, reducing the number of outstanding shares and increasing the par value of its ordinary shares from $0.0135 to $0.135 per share. In conjunction with the reverse split, the company’s CUSIP number…
AInvest Wire · Jun 24, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.